OrderMedications.org - buy hundreds cheap rx medicines online!

OrderMedications.org gives you the chance to buy cellcept pills and quality Surgery drugs at discount prices from the privacy of your home.

Generic Cellcept Mycophenolate mofetil 250/500mg

Each dose of Cellcept must be taken with a full glass of water. Each dose of Cellcept must be taken on an empty stomach, preferably 1 or 2 hours before meals unless otherwise directed by your doctor. The usual frequency of taking Cellcept is twice a day. You will need frequent blood checks during the first few months you are receiving the medicine.Keep out of the sun. If you cannot avoid being in the sun, wear protective clothing and use sunscreen.

Package	Price	Per Pill	Order
250mg × 10 pills	$119.40	US $ 11.94
250mg × 20 pills	$196.80	US $ 9.84
250mg × 30 pills	$274.20	US $ 9.14

Package	Price	Per Pill	Order
500mg × 10 pills	$212.40	US $ 21.24
500mg × 20 pills	$382.80	US $ 19.14

Information For Patients

Inform patients that they need repeated appropriate laboratory tests while they are taking CellCept. Drug interaction studies with mycophenolate mofetil have been conducted with acyclovir, antacids, cholestyramine, cyclosporine, ganciclovir, oral contraceptives, sevelamer, trimethoprim/sulfamethoxazole, norfloxacin, and metronidazole. Drug interaction studies have not been conducted with other drugs that may be commonly administered to renal, cardiac or hepatic transplant patients. However, MPAG and acyclovir plasma AUCs were increased 10.6% and 21.9%, respectively.

Adverse Reactions

Following single-dose administration of 1.5 g mycophenolate mofetil to 12 healthy volunteers pretreated with 4 g tid of cholestyramine for 4 days, MPA AUC decreased approximately 40%. Cyclosporine (Sandimmune) pharmacokinetics (at doses of 275 to 415 mg/day) were unaffected by single and multiple doses of 1.5 g bid of mycophenolate mofetil in 10 stable renal transplant patients. The mean (SD) AUC(0 - 12h) and C max of cyclosporine after 14 days of multiple doses of mycophenolate mofetil were 3290 (822) ngh/mL and 753 (161) ng/mL, respectively, compared to 3245 (1088) ngh/mL and 700 (246) ng/mL, respectively, 1 week before administration of mycophenolate mofetil.

Drug Interactions

Elderly patients (greater than 65 years), particularly those who are receiving CellCept as part of a combination immunosuppressive regimen, may be at increased risk of certain infections (including cytomegalovirus [CMV] tissue invasive disease) and possibly gastrointestinal hemorrhage and pulmonary edema, compared to younger individuals Safety data are summarized below for all active-controlled trials in renal (2 trials), cardiac (1 trial), and hepatic (1 trial) transplant patients. Approximately 53% of the renal patients, 65% of the cardiac patients, and 48% of the hepatic patients have been treated for more than 1 year. The adverse event profile of CellCept Intravenous was determined from a single, double-blind, controlled comparative study of the safety of 2 g/day of intravenous and oral CellCept in renal transplant patients in the immediate posttransplant period (administered for the first 5 days).

Overdosage

Coadministration of mycophenolate mofetil (1 g) and acyclovir (800 mg) to 12 healthy volunteers resulted in no significant change in MPA AUC and C max. Absorption of a single dose of mycophenolate mofetil (2 g) was decreased when administered to ten rheumatoid arthritis patients also taking Maalox TC (10 mL qid). The C max and AUC(0 - 24h) for MPA were 33% and 17% lower, respectively, than when mycophenolate mofetil was administered alone under fasting conditions. In renal transplant patients, mean MPA exposure (AUC 0-12h) was approximately 30-50% greater when mycophenolate mofetil is administered without cyclosporine compared with when mycophenolate mofetil is coadministered with cyclosporine.

There was no significant effect on mean MPA AUC 0-48h when mycophenolate mofetil was concomitantly administered with norfloxacin or metronidazole separately. The measured value for renal clearance of MPAG indicates removal occurs by renal tubular secretion as well as glomerular filtration. Consistent with this, coadministration of probenecid, a known inhibitor of tubular secretion, with mycophenolate mofetil in monkeys results in a 3-fold increase in plasma MPAG AUC and a 2-fold increase in plasma MPA AUC. Thus, other drugs known to undergo renal tubular secretion may compete with MPAG and thereby raise plasma concentrations of MPAG or the other drug undergoing tubular secretion. Drugs that alter the gastrointestinal flora may interact with mycophenolate mofetil by disrupting enterohepatic recirculation.